Growth Factor Receptor Directed Therapy in Cancer

Pietras, Richard Joseph

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: First Independent Research Support & Transition (FIRST) Awards (R29)
• Project #: 5R29CA060835-02
• Application #: 2101603
• Study Section: Experimental Therapeutics Subcommittee 1 (ET)
• Project Start: 1995-02-01
• Project End: 2000-01-31
• Budget Start: 1996-02-01
• Budget End: 1997-01-31
• Support Year: 2
• Fiscal Year: 1996

Institution

• Name: University of California Los Angeles
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 119132785
• City: Los Angeles
• State: CA
• Country: United States
• Zip Code: 90095

Publications

Li, Dan; Williams, Jon I; Pietras, Richard J (2002) Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 21:2805-14

Pietras, R J; Poen, J C; Gallardo, D et al. (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-55

Pietras, R J; Arboleda, J; Reese, D M et al. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-46